40+ results for "IoT"
KRTL International Explores U.S.-Bolivia Critical Minerals Pathways Following Mining Cooperative LOI and Development Framework
Company reviews historical antimony assay information, awaits additional tungsten-related materials and advances documentation-stage evaluation through KRTL BlueSpot and its consultant network Lakewood, CO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company") today announced that KRTL International Corp., the Company's international and federal-facing subsidiary, has executed a Letter of Intent and Project Development Cooperation Framework with a Bolivi
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting
IMC 2026: From Connectivity to Deployment at Scale, Fibocom Strengthens Its IoT Presence in India
NEW DELHI , Oct. 9, 2026 -- Fibocom (300638.SZ; 0638.HK), a leading global provider of wireless communication modules and AI solutions, presented its latest portfolio at India Mobile Congress 2026, as growing adoption of 5G, energy digitalization and connected mobility creates new demand for IoT deployment across India. At the show, Fibocom highlighted applications spanning wireless broadband, energy, vehicle and asset management. Its FWA portfolio included 5G modules as well as CPE, ODU and MiFi solutions, while smart meters, vehicle tracking devices and EV battery trackers demonstrated how cellular connectivity is moving deeper into vertical applications.
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement. Under the agreement, Rua will import, distribute and sell PharmAla’s pharmaceutical-grade LaNeo™ MDMA in New Zealand. The agreement follows Medsafe’s approval, on 4 September 2026, of two psy
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologou
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week PISCATAWAY, N.J. and SANTA CLARA, Calif. , Oct. 8, 2026 / PRNewswire / -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest , a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript s wet lab validation and data generation capabilities and NVIDIA s accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.
Finance Day 2026: Leipzig wird erneut zum Treffpunkt für Wachstumskapital in den Life Sciences
Investoren, Unternehmer und Finanzierungsexperten diskutieren am 22. Oktober in der BIO CITY LEIPZIG über die Zukunft der Life-Sciences-Finanzierung Leipzig, 08. Oktober 2026 – Wie gelingt die Finanzierung von Innovationen in Biotechnologie, Medizintechnik, Diagnostik, Digital Health und Bioökonomie? Welche Kapitalquellen stehen jungen Unternehmen und wachstumsstarken Scale-ups zur Verfügung? Und welche Bedeutung kann der Kapitalmarkt für die nächste Wachstumsphase spielen? Antworten auf diese F
Fibocom and Grid-OS Accelerate IoT Deployment at Scale in India at IMC 2026
NEW DELHI , Oct. 8, 2026 -- Fibocom, a leading global provider of wireless communication modules and AI solutions, is collaborating with India-based IoT ODM Grid-OS to advance smart payment and vehicle tracking applications in India. At IMC 2026, Grid-OS is showcasing a Payment Soundbox powered by Fibocom s LE270 LTE Cat 1 bis module , alongside two 4G Vehicle Trackers based on Fibocom s LE250 series LTE Cat 1 bis modules . India s IoT market is moving rapidly toward large-scale deployment. NPCI data shows that UPI transactions reached 24.51 billion in August 2026 , while growing applications such as vehicle tracking are creating increasingly diverse requirements for reliable connectivity, low power consumption and positioning capabilities.
Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program
LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale San Raffaele S.r.l. (OSR), to discuss the initial research program for evaluating an encapsulated beta-cell replacement approach for insulin-dependent diabetes. The meeting brought together Prof. Lorenzo Piemonti, Director of the Diabetes Research Inst
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced the successful closing of a $150 million Series B financing. The financing was co-led by Nextech Invest and Norwest
Asset Performance Management Market Surges to $4.32 billion at a CAGR 10.3% by 2032 | Report by MarketsandMarkets™
Delray Beach, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the global Asset Performance Management Market is projected to grow from USD 2.40 billion in 2026 to USD 4.32 billion by 2032, at a CAGR of 10.3%, driven by the rising adoption of predictive maintenance, real-time monitoring, advanced analytics, IoT, and digital twins. APM platforms help energy, utilities, transportation, and manufacturing organizations optimize maintenance, extend asset lifecycles, reduce downt
Machine Safety Market to Reach USD 7.45 Billion by 2030, Growing at 5.7% CAGR, Says MarketsandMarkets™
Delray Beach, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The global Machine Safety Market is projected to reach USD 7.45 billion by 2030 from USD 5.66 billion in 2025, at a CAGR of 5.7%, according to a new report by MarketsandMarkets™. The market is growing due to the adoption of automation and Industry 4.0 technologies, which increase machinery complexity and workplace risks. Strict global regulations are driving compliance in high-risk industries, while the focus on predictive analytics and IoT-ena
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitali
New Report: 400+ Global Life Science Leaders Bullish Despite Market Uncertainty
As AI usage takes shape and market pressures persist, CRB's Horizons: Life Sciences 2026 report explores how manufacturers are investing in facilities, advanced technologies and workforce development Horizons: Life Sciences 2026 report Published annually by CRB, Horizons: Life Sciences explores the trends shaping the future of pharmaceutical and biotechnology manufacturing. KANSAS CITY, Mo., Oct. 06, 2026 (GLOBE NEWSWIRE) -- CRB’s newly released Horizons: Life Sciences 2026 report finds manufact
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for smal
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models LEUVEN, Belgium, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Rewind Therapeutics ("Rewind"), a biotechnology company developing small-molecule therapies to restore myelin in demyelinating diseases, today anno
30 Investors, Founders and Policymakers join DeepVerse, Startup Policy Forum's Centre for DeepTech Innovation
Startup Policy Forum (SPF) launches DeepVerse, its Centre for DeepTech Innovation, a multi-stakeholder platform to accelerate India s deeptech ecosystem The platform features an 18-member high-powered Advisory Board comprising investors, founders, global technology firms, policymakers, government, and academia Ten leading VC firms come together on the platform to promote India s deeptech ecosystem including Accel India, Lightspeed, Bessemer Venture Partners, Speciale Invest, Endiya Partners, Crane Ventures, Avaana Capital, Iron Pillar, Stride Asset Management and Beenext. The Centre will focus on ten deeptech sub-sectors, including semiconductors, advanced manufacturing, spacetech, quantum tech, defence tech, biotech & healthtech, cleantech & energy, drones & aerospace, electric vehicles, robotics. DeepVerse builds on 100DesiDeepTechs, SPF s national initiative with MeitY Startup Hub (MSH), Startup India (DPIIT) and IIT Madras, which identified a cohort of India s 100 leading deeptech startups in May 2026. DeepVerse will soon launch its extensive report to highlight policy actionables across the ten sectors
Elliott Management Statement on L'Air Liquide S.A.
LONDON , Oct. 6, 2026 -- Elliott Investment Management L.P. and Elliott Advisors (UK) Limited ( Elliott ), which advise funds that together hold a significant economic interest in L Air Liquide S.A. ( Air Liquide or the Company ), today issued the following statement in connection with the Company s 2026 Capital Markets Day: Elliott welcomes the value-creating initiatives announced on Monday as part of Air Liquide s new strategic plan, including its target to improve margins by 400 to 600 basis points by 2030 and its first-ever large share buyback, which we believe should start immediately. The Company s targets for annual growth of 5% in revenue and 10% in EPS through 2030 highlight the strength of its business and the opportunities in AI, electronics, healthcare and space.
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries. Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the mark
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant th
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule
Lanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology Capabilities
Flagship Biosciences https://flagshipbio.com/ Ampersand Capital Partners https://ampersandcapital.com/ Boulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and digital pathology company backed by Ampersand Capital Partners. The combined o
KRTL Holding Group Advances RAYEL Into Next Phase with Definitive CIQ Agreement
Agreement brings together RAYEL’s scientific foundation, KRTL’s U.S. commercialization strategy and expanding regulatory, API and research capabilities Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company") today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. ("CIQ") for the continued devel
Cannara Expands International Supply Agreement with Curaleaf
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., is pleased to announce an expansion of its long-term international supply agreement (the “Agreement”) with Curaleaf International Limited (“Curaleaf”), previously announced on July 14
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program HIGHLIGHTS Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”) Benuvia operates an 83,000-square-foot, DEA-registered controll
EVIDENT Completes Acquisition of CrestOptics S.p.A.
NEEDHAM, Mass. , Oct. 5, 2026 -- Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The acquisition broadens Evident s life science imaging portfolio and deepens its capability in high-speed, high-content 3D imaging for research, pharma, and biotech applications. Founded in 2011, CrestOptics designs and manufactures confocal spinning disk and structured illumination microscopy (SIM) modules that integrate with microscope platforms from leading manufacturers worldwide. Its portfolio includes the X-Light family of spinning disk confocal systems, featuring precise optical sectioning and uniform illumination across a class-leading field of view; the compact CICERO widefield and spinning disk solution, which brings highly capable entry-level confocal within reach of any lab; and DeepSIM, a Lattice SIM super-resolution module that delivers sub-diffraction imaging with the accessibility of a widefield system. Used in laboratories around the world, CrestOptics products are built to be universally accessible tools that advance discovery without barriers.
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on Oc
AI Is Reshaping Gene Transfer Technologies — $258.7 Billion in VC Signals a Structural Shift in Biotech Investment
“BCC Research examines how AI is improving gene transfer technologies through data-driven design, delivery optimization and advanced analysis of complex biological and genomic data, supporting more precise and efficient therapeutic development.” Boston, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is triggering a fundamental transformation in gene transfer technologies, compressing decade-long development timelines into months, unlocking new vector design paradigms, and attracting u
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across industries. COPENHAGEN, Denmark, October 1 – Novonesis today announced the completion of its acquisition of MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications and a proven track record in bioethanol. All regulator
TransPerfect Acquires Synterex to Expand Medical Writing Expertise and AI-Enabled Regulatory Solutions
Key Takeaways: TransPerfect Acquires Synterex Synterex specializes in clinical and regulatory writing and development solutions for the biotech and pharmaceutical industries. Synterex’s AgileWriter.ai® software supports AI-assisted authoring, review, and content management to accelerate document workflows and reduce manual effort. The combined offering delivers a single integrated workflow, reducing handoffs and providing greater traceability across the content lifecycle. NEW YORK, Oct. 01, 2026
Veea Announces TROLLEE Agreement for Phased Deployment of VeeaONE to 1,000 Unattended Stores
TROLLEE plans to run its smart retail applications on VeeaONE, combining local AI, secure connectivity and remote management NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Veea Inc. (NASDAQ: VEEA) today announced an agreement with TROLLEE Holdings Limited for the phased deployment of VeeaONE solutions across 1,000 unattended stores, beginning with up to 50 locations. Depending on store size and layout, a typical configuration is expected to include one or more VeeaHubs integrated with an AI compute
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
Board additions bring diabetes-development and company-building expertise as Caspian prepares KO-7246 for advancement into clinical testing SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”), a biotechnology company developing menin inhibitors for diabetes and other cardiometabolic diseases, today announced the appointments of Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to its Board of Directors. Caspian recently launched with $50 million in financing to adva
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary E
Your AI Twin Could Save Your Life: UVM Awarded up to $38M to Build ‘Digital Twins’ for Treating Critically Ill Patients
Surgeon's innovative approach attracts federal investment for potential to shorten ICU stays by as much as 25% University of Vermont trauma surgeon and researcher Gary An is developing AI "digital twins" to help treat critically ill patients. Credit: Jeff Paxton/University of Vermont Burlington, Vt., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BURLINGTON, Vt.—What if doctors could test a customized treatment on a virtual version of a critically ill patient before administering it in real life? That’s the
Lithium Batteries Market to Reach $4.7 Billion by 2031, Driven by Surging Demand for Medical Devices and Industrial IoT Deployment
“According to BCC Research, the global lithium battery market is projected to grow from $3.7 billion in 2026 to $4.7 billion by 2031, at a CAGR of 4.7%, supported by expanding demand for advanced battery and energy storage technologies.” Boston, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The global lithium batteries market is projected to grow from $3.6 billion in 2025 to $4.7 billion by 2031, reflecting a compound annual growth rate (CAGR) of 4.7% over the forecast period 2026–2031, according to BCC Re
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture’s signature technology, Cell-in-a-Box ® capsules. After the successful completion of comprehensive adventitious a
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis Investment comes ahead of Phase 2b topline data, expected in H1 2027 REDWOOD CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing fi